N/A
Completed N=22
A Pilot and Feasibility Study of Mobile-Based Asthma Action Plans
Source: ClinicalTrials.gov NCT01514760 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Feb 2016
Primary outcomePrimary: Mobile Asthma Action Plan (AAP) Usage — 4.3 days per week
Summary
Investigators from University of Arkansas for Medical Sciences Department of Pediatrics and University of Arkansas for Medical Sciences Center for Distance Health will collaborate to develop a mobile-based Asthma Action Plan application to improve asthma self-management skills specifically targeting adolescents. The investigators hypothesize that an interactive, mobile-based asthma action plan will be a feasible means of reinforcing long-term asthma management guidelines as well as delivering acute management instructions to adolescents with asthma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mobile Asthma Action Plan (AAP) Usage |
4.3 | — |
| SECONDARY Number of Participants That Utilized the Asthma Action Plan |
11 | — |
| SECONDARY Asthma Self-Efficacy for Adolescent Children |
62.8; 57.2 | — |
| SECONDARY Asthma Control Test™ Scores |
20.3; 19.4; 15.3; 19.1 | 0.03 sig |
Eligibility Criteria
Inclusion Criteria
- Age ≥ 12 and ≤ 17 years.
- Mild to severe persistent asthma or poorly controlled asthma. If a child has used a preventive medication in the past, but reports no use of the medication in the prior 3 months, we will assess severity.
- Children not using a preventive medication at baseline: We will assess for mild persistent to severe persistent asthma. Any one of the following, during the prior 4 weeks (as defined by parent interview) will determine severity:
- An average of >2 days per week with asthma symptoms
- >2 days per week with rescue medication use
- ≥2 nights per month awakened with nighttime symptoms
- Minor limitation of activity
- ≥2 episodes of asthma during the past year that have required systemic corticosteroids.
- Children using a preventive medication at baseline: We will assess for poorly controlled asthma. Any 1 of the following, during the prior 4 weeks (as defined by parent interview in the waiting room) will determine control:
- An average of >2 days per week with asthma symptoms
- >2 days per week with rescue medication use
- ≥2 nights per month awakened with nighttime symptoms
- Some limitation of activity
- ≥2 episodes of asthma during the past year that have required systemic corticosteroids.
Exclusion Criteria
- Significant underlying respiratory disease other than asthma (such as cystic fibrosis or chronic lung disease) that could potentially interfere with asthma-related outcome measures.
- Significant co-morbid conditions (such as moderate to severe developmental delay, i.e. special education classroom or diagnosis) that could preclude participation in an education-based intervention.
- Inability to speak or understand English (child or parent).
- Children in foster care or other situations in which consent cannot be obtained from a guardian.
- Prior enrollment in the study.
Data sourced from ClinicalTrials.gov (NCT01514760). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.